Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Maspero

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|September 6, 2022
Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST studyJorge F Maspero, Guido Cardona, Patricia Schonffeldt, et al.
Journal of Asthma and Allergy|July 5, 2022
Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma ExacerbationNicola A Hanania, Jorge F Maspero, David M G Halpin, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 1, 2024
Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation StudyJorge F Maspero, Anju T Peters, Kenneth R Chapman, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 1, 2022
Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trialsAnju T Peters, Zachary M Soler, Robert C Kern, et al.
The Journal of Allergy and Clinical Immunology|January 10, 2022
Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil countClaus Bachert, Ana R Sousa, Joseph K Han, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 10, 2022
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid DoseChristian Domingo, Jorge F Maspero, Mario Castro, et al.
The Journal of Allergy and Clinical Immunology|January 25, 2024
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthmaLeonard B Bacharier, Ian D Pavord, Jorge F Maspero, et al.
Journal of Asthma and Allergy|March 14, 2023
Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen SensitizationJonathan Corren, David J Jackson, Thomas B Casale, et al.
Advances in Therapy|May 5, 2018
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe AsthmaWilliam W Busse, Jorge F Maspero, Klaus F Rabe, et al.
Allergy|April 14, 2023
Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthmaNikolaos G Papadopoulos, Stanley J Szefler, Leonard B Bacharier, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|September 6, 2022
Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST studyJorge F Maspero, Guido Cardona, Patricia Schonffeldt, et al.
Journal of Asthma and Allergy|July 5, 2022
Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma ExacerbationNicola A Hanania, Jorge F Maspero, David M G Halpin, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 1, 2024
Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation StudyJorge F Maspero, Anju T Peters, Kenneth R Chapman, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 1, 2022
Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trialsAnju T Peters, Zachary M Soler, Robert C Kern, et al.
The Journal of Allergy and Clinical Immunology|January 10, 2022
Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil countClaus Bachert, Ana R Sousa, Joseph K Han, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 10, 2022
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid DoseChristian Domingo, Jorge F Maspero, Mario Castro, et al.
The Journal of Allergy and Clinical Immunology|January 25, 2024
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthmaLeonard B Bacharier, Ian D Pavord, Jorge F Maspero, et al.
Journal of Asthma and Allergy|March 14, 2023
Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen SensitizationJonathan Corren, David J Jackson, Thomas B Casale, et al.
Advances in Therapy|May 5, 2018
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe AsthmaWilliam W Busse, Jorge F Maspero, Klaus F Rabe, et al.
Allergy|April 14, 2023
Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthmaNikolaos G Papadopoulos, Stanley J Szefler, Leonard B Bacharier, et al.
Pageof 6